Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213828 | 1.00 | CES2 (0.48) | CES2CES1CYP3A4GABRA1GABRB2 | |
| SCHEMBL14088059 | 1.00 | CES2 (0.48) | CES2CES1CYP3A4GABRA1GABRB2 | |
| SCHEMBL625219 | 1.00 | CES2 (0.48) | CES2CES1CYP3A4GABRA1GABRB2 | |
| SCHEMBL29609066 | 1.00 | CES2 (0.48) | CES2CES1CYP3A4GABRA1GABRB2 | |
| Phthalic Acid SCHEMBL3628213 | 0.84 | CES2 (0.54) | CES2CES1CYP3A4MEN1KMT2A | |
| Phthalic Acid SCHEMBL3628215 | 0.84 | CES2 (0.54) | CES2CES1CYP3A4MEN1KMT2A | |
| SCHEMBL9667214 | 0.83 | PDE2A (0.50) | CES2CES1CYP3A4GABRA1GABRB2 | |
| SCHEMBL11602791 | 0.81 | CES2 (0.54) | CES2CES1CYP3A4ACHEIDO1 | |
| SCHEMBL23363630 | 0.81 | CES2 (0.52) | CES2CES1CYP3A4GABRA1GABRB2 | |
| SCHEMBL5684729 | 0.81 | CES2 (0.46) | CES2CES1CYP3A4GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119776301-A | Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-10-28 | — | — | US | disclosed |
| CN-120718870-A | Alcohol dehydrogenase mutant with improved stereoselectivity and method for preparing (R) -o-fluorophenylethanol by using alcohol dehydrogenase mutant | 杭州微远生物科技有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-120718870-A | Alcohol dehydrogenase mutant with improved stereoselectivity and method for preparing (R) -o-fluorophenylethanol by using alcohol dehydrogenase mutant | 杭州微远生物科技有限公司 | 2025-09-30 | — | — | CN | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| CN-119776301-A | Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119614529-A | Short-chain dehydrogenase, engineering bacteria and application thereof in asymmetric reduction of potential chiral carbonyl compounds | 杭州文德阶生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010068775-A2 | ALKYNE ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20080227978-A1 | Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields | THE UNIVERSITY OF NOTTINGHAM | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454530-B2 | Amido cyclohexane acid derivatives as LPA receptor inhibitors | LPAR1, LPAR2, LPAR3 | CES2 2216/4885CES1 97/4885CYP3A4 4682/4885 |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CES2 2682/4885CES1 747/4885CYP3A4 4714/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | CES2 2325/4885CES1 2001/4885CYP3A4 3789/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | CES2 4265/4885CES1 3291/4885CYP3A4 3927/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CES2 2696/4885CES1 859/4885CYP3A4 4750/4885 |
| US-20080227978-A1 | Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields | ADH5, ADH1C, CYP2E1 | CES2 352/4885CES1 1840/4885CYP3A4 14/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | CES2 1759/4885CES1 1510/4885CYP3A4 296/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | CES2 4595/4885CES1 2880/4885CYP3A4 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.